C12N 2320/53
Reducing unwanted side-effects
Official title: reducing unwanted side-effects
C12N2320/53 (Reducing unwanted side-effects) appears on 179 US grants and 322 published applications in this corpus.
Search patents in C12N- Granted patents
- 179
- Published applications
- 322
- Assignees
- 123
- Inventors
- 533
- Latest grant
- 16 Jun 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2007 | 0 | 1 |
| 2008 | 0 | 2 |
| 2009 | 0 | 2 |
| 2010 | 0 | 10 |
| 2011 | 1 | 14 |
| 2012 | 4 | 9 |
| 2013 | 10 | 6 |
| 2014 | 8 | 11 |
| 2015 | 6 | 15 |
| 2016 | 8 | 28 |
| 2017 | 18 | 25 |
| 2018 | 12 | 9 |
| 2019 | 15 | 18 |
| 2020 | 16 | 21 |
| 2021 | 13 | 34 |
| 2022 | 24 | 28 |
| 2023 | 14 | 30 |
| 2024 | 8 | 31 |
| 2025 | 17 | 18 |
| 2026 | 5 | 10 |
By publication year. 2026 runs to 8 Oct.
Recent patents
- Methods and compositions for inhibition of CRISPR re-cleavage events16 Jun 2026US 12,655,422 B2Integrated Dna Technologies, Inc.
- Dual guide CRISPR hybrid DNA/RNA polynucleotides and methods of use2 Jun 2026US 12,644,138 B2Caribou Biosciences, Inc.
- Compounds and methods for reducing ATXN3 expression5 May 2026US 12,618,069 B2Ionis Pharmaceuticals, Inc.
- Production method for genome-edited cells28 Apr 2026US 12,612,648 B2Kyushu University, National University Corporation
- Linkage modified oligomeric compounds and uses thereof7 Apr 2026US 12,595,482 B2Ionis Pharmaceuticals, Inc.
- Compositions of Asymmetric Interfering RNA and Uses Thereof3 Sep 2026US 2026/0258412 A11Globe Health Institute LLC
- Sirna structures for high activity and reduced off target27 Aug 2026US 2026/0250686 A1Nitto Denko Corporation
- Chemically Modified saRNA Compositions and Methods of Use30 Jul 2026US 2026/0218178 A1Mina Therapeutics Limited
- Compounds and Methods for Reducing ATXN3 Expression2 Jul 2026US 2026/0185098 A1Ionis Pharmaceuticals, Inc.
- Production method for genome-edited cells2 Jul 2026US 2026/0185122 A1Kyushu University, National University Corporation
Most cited
By later US patents
- Single stranded extended dicer substrate agents and methods for the specific inhibition of gene expression95US 8,349,809 B2Dicerna Pharmaceuticals, Inc. · 2013
- Switchable gRNAs comprising aptamers94US 9,228,207 B2President and Fellows of Harvard College · 2016
- Reduced size self-delivering RNAi compounds92US 8,796,443 B2RXi Pharmaceuticals Corporation · 2014
- MRNA-sensing switchable gRNAs90US 9,340,799 B2President and Fellows of Harvard College · 2016
- Extended DNA-sensing GRNAS90US 9,340,800 B2President and Fellows of Harvard College · 2016